<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1298">
  <stage>Registered</stage>
  <submitdate>11/09/2006</submitdate>
  <approvaldate>11/09/2006</approvaldate>
  <nctid>NCT00377858</nctid>
  <trial_identification>
    <studytitle>Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)</studytitle>
    <scientifictitle>Comparison of Two Approaches to Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control on Oral Therapy: Comparison of Premixed Insulin Lispro Mid Mixture With Separate Basal and Bolus Insulin Injections</scientifictitle>
    <utrn />
    <trialacronym>IOOX</trialacronym>
    <secondaryid>F3Z-MC-IOOX</secondaryid>
    <secondaryid>10936</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Insulin lispro mid mixture (MM)
Treatment: drugs - Insulin glargine

Experimental: Insulin Lispro Mid Mixture - Insulin lispro mid mixture (MM) up to three times a day (TID)

Active Comparator: Insulin Glargine - Insulin glargine daily with insulin lispro at mealtime (up to 3 injections) as needed.


Treatment: drugs: Insulin lispro mid mixture (MM)
Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks

Treatment: drugs: Insulin glargine
Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Hemoglobin A1c (HbA1c) at 36 Week Endpoint</outcome>
      <timepoint>36 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Hemoglobin A1c (HbA1c) at Interval Visits</outcome>
      <timepoint>12, 24, and 36 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Patients Who Achieved Hemoglobin A1c Less Than or Equal to 6.5%, Greater Than 6.5%, Less Than 7%, Greater Than or Equal to 7%, Less Than or Equal to 7%, and Greater Than 7% at Interval Visits and Endpoint</outcome>
      <timepoint>12-24-36 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>7-point Self-monitored Blood Glucose Profiles</outcome>
      <timepoint>Baseline, 12-24-36 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Glycemic Variability</outcome>
      <timepoint>Baseline, 12-24-36 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Patients With at Least One Self-reported Hypoglycemic Episode, Including Nocturnal (and Non-nocturnal) Hypoglycemia</outcome>
      <timepoint>Baseline to 36 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>30-Day Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including Nocturnal and Non-Nocturnal)</outcome>
      <timepoint>Baseline to 36 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Patients With at Least One Severe Hypoglycemia Episode</outcome>
      <timepoint>Baseline to 36 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Endpoint Insulin Dose Per Body Weight; Total, Basal, and Prandial</outcome>
      <timepoint>36 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Endpoint Insulin Dose; Total, Basal, and Prandial</outcome>
      <timepoint>36 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Insulin Injections Per Day</outcome>
      <timepoint>Weeks 12, 24, 30, 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Absolute Body Weight at 36 Week Endpoint</outcome>
      <timepoint>Baseline, 36 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have type 2 diabetes

          -  Have been receiving oral antihyperglycemic medications (OAM) without insulin including
             at least two of the following at maximally tolerated doses, AND meet the minimum
             dosing criteria shown: Metformin 1500 mg/day, Sulfonylurea 1/2 the maximum daily dose,
             according to package insert, Thiazolidinedione (TZD) 30 mg/day pioglitazone or 4
             mg/day rosiglitazone. The OAMs also must be used in accordance with the product label

          -  Have a hemoglobin A1c greater than or equal to 7.5% and less than or equal to 12.0%.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Are taking a TZD dose greater than what is indicated in combination with insulin
             according to the TZD label.

          -  Are taking any other glucose-lowering agents not mentioned in Inclusion Criterion.

          -  Have taken acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide in
             the past 6 weeks or for a total of 30 days or more in the last 24 weeks.

          -  Have a body mass index greater than 40 kg/m2.

          -  Have had more than one episode of severe hypoglycemia in the last24 weeks

          -  Are pregnant, intend to be pregnant during the course of the study or are
             breastfeeding

          -  Have clinically significant cardiac, renal, hematologic, oncologic, or hepatic disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>484</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Keswick</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Fitzroy</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Fremantle</hospital>
    <postcode>5035 - Keswick</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>6160 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Mantes La Jolie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Menton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Goyang-Si/Kyunggi-Do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Kwang Ju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Chihuahua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Arkhangelsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Almeria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Bilbao</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A study of patients with type 2 diabetes and inadequate glycemic control on two or more oral
      antihyperglycemic agents comparing adding insulin lispro mid mixture to the oral
      antihyperglycemic agents to adding insulin glargine to the oral antihyperglycemic agents.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00377858</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>